TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Biotec Betaglucans AS
Closing information (x1000 EUR)
| Closing information | 2024/01 | 2023/01 | 2022/01 |
| Turnover |
2,846
|
1,496
|
2,587 |
| Financial expenses |
157
|
199
|
15 |
| Earnings before taxes |
301
|
218
|
6,605 |
| Total assets |
2,928
|
2,089
|
2,625 |
| Current assets |
2,226
|
1,815
|
2,408 |
| Current liabilities |
1,696
|
835
|
907 |
| Equity capital |
1,232
|
1,254
|
1,719 |
| - share capital |
88
|
92
|
100 |
Financial ratios
| Fiscal year | 2024/01 | 2023/01 | 2022/01 |
| Solvency |
42.1%
|
60.0%
|
65.5% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
10.6%
|
14.6%
|
255.3% |
| Return on assets (ROA) |
15.6%
|
20.0%
|
252.2% |
| Current ratio |
131.2%
|
217.4%
|
265.5% |
| Return on equity (ROE) |
24.4%
|
17.4%
|
384.2% |
| Change turnover |
1,420
|
-897
|
-2,369 |
| Change turnover % |
100%
|
-37%
|
-48% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/01 | 2023/01 | 2022/01 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.